Medicine information PLEGRIDY 63mcg / 94mcg solution for injection in pre-filled syringe

Product code:
W65154001
Quantity:
1
Indicated for:
multiple sclerosis
Route of administration:
injectable
Substance:
peginterferon beta-1A (interferon)
ATC
L03AB13 — Antineoplastic and immunomodulating agents | Immunostimulants | Immunostimulants | Interferons
Peginterferon beta-1a is a medication used in the treatment of relapsing multiple sclerosis. It works by modulating the immune response and reducing inflammation, helping to decrease the frequency of relapses and slow disease progression.

The medication is administered subcutaneously, as directed by a doctor, usually once every two weeks. It is important for patients to follow the treatment regimen and inform the doctor of any unusual symptoms.

Patients should be aware of potential side effects, such as injection site reactions, flu-like symptoms, or fatigue. It is important to inform the doctor of any unusual symptoms.

Common side effects include injection site reactions, flu-like symptoms, and fatigue. In rare cases, severe reactions such as depression or liver disorders may occur. Patients should be informed of these risks before use.

General data about PLEGRIDY 63mcg / 94mcg

Substance:
peginterferon beta-1A
Date of latest medicines list:
01-12-2018
Product code:
W65154001
Strength:
63mcg / 94mcg
Pharmaceutical form:
solution for injection in pre-filled syringe
Quantity:
1
Product type:
Original
Prescription status:
P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.

Marketing authorisation

Manufacturer:
BIOGEN (DENMARK) MANUFACTURING APS - DANEMARCA
Holder:
BIOGEN NETHERLANDS B.V. - OLANDA
Number:
934/2014/01
Shelf life:
3 years

Pharmaceutical forms available for peginterferon beta-1A

Official documents

The SmPC text is not displayed because a match to this medicine, strength and pharmaceutical form has not been confirmed.

Added to database:
31/07/2014
Source record updated:
11/02/2026